Bristol-Myers Squibb Company #BMY announced the FDA has lifted a partial clinical hold placed on CA209-602 (CheckMate-602), an open-label Phase 3 study evaluating Opdivo to pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
http://stocksnewsfeed.com/?s=Bristol-Myers+Squibb+Company